Is Fennec Pharmaceuticals Inc. (FENC) a Buy, Sell, or Hold?
NASDAQ : FENC
Fennec Pharmaceuticals Inc.
$10.5 USD
$0.06 (0.57%)
- Volume
- 186.29K
- Average Volume
- 272.38K
- Market Capitalization
- $300.09M
- P/E Ratio
- -34.19
- Dividend Yield
- 0.00%
- Price Target
- $16.00
- Year High
- $11.31
- Year Low
- $5.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.98
Company Overview
NASDAQ
Jeffrey S. Hackman
Biotechnology
Healthcare
FENC
35
US
USD
Liquidity Metrics
0.00
6.98
6.78
4.19
0.00
Sales & Valuation
$44.64M
5.88
9.57
-51.95
-0.17
Profitability
-$0.36
-$9.74M
-16.42%
-16.22%
-54.75%
-11.66%
P/E Metrics
-34.19
-2.45
-2.45
Analyst Price Target & Rating
$16.00
$16.00
$16.00
1/5
7 Analysts
-34.38%
Poll Results
About Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina. ...
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
2026-07-06 14:26:04
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-06-22 06:00:00
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 22, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-06-15 06:00:00
RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Fennec Announces Results of Annual Meeting
2026-06-10 16:30:00
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.
Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter
2026-05-23 10:06:55
Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference.
2026-05-21 18:01:00
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-18 16:30:00
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to purchase an aggregate of 859 shares. The Stock Options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
2026-05-14 12:20:42
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Fennec Pharmaceuticals Inc. (FENC) stock price?
-
Fennec Pharmaceuticals Inc.(NASDAQ:FENC) stock price is $10.5 in the last trading session. During the trading session, FENC stock reached the peak price of $11.31 while $5.65 was the lowest point it dropped to. The percentage change in FENC stock occurred in the recent session was 0.57% while the dollar amount for the price change in FENC stock was $0.06.
-
FENC's industry and sector of operation?
-
The NASDAQ listed FENC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of FENC?
-
Pierre S. Sayad | Chief Medical Officer
Jeffrey S. Hackman | Chief Executive Officer & Director
Lei Fang | President of Pharstat Inc
Mark Gowland | Controller
Robert C. Andrade | Chief Financial Officer -
How many employees does FENC have?
-
Number of FENC employees currently stands at 35. FENC operates from 68 TW Alexander Drive, Research Triangle Park, NC 27709, US.
-
Link for FENC official website?
-
Official Website of FENC is: https://www.fennecpharma.com
-
How do I contact FENC?
-
FENC could be contacted at phone #919 636 4530 and can also be accessed through its website. FENC operates from 68 TW Alexander Drive, Research Triangle Park, NC 27709, US.
-
How many shares of FENC are traded daily?
-
The average number of FENC shares traded daily for last 3 months was 272.38K.
-
What is the market cap of FENC currently?
-
The market value of FENC currently stands at $300.09M with its latest stock price at $10.5